|
Gene: CREBBP |
Gene summary for CREBBP |
Gene summary. |
Gene information | Species | Human | Gene symbol | CREBBP | Gene ID | 1387 |
Gene name | CREB binding protein | |
Gene Alias | CBP | |
Cytomap | 16p13.3 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | Q92793 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1387 | CREBBP | CA_HPV_1 | Human | Cervix | CC | 4.57e-04 | 5.19e-02 | 0.0264 |
1387 | CREBBP | CCI_1 | Human | Cervix | CC | 1.23e-03 | 7.23e-01 | 0.528 |
1387 | CREBBP | CCI_2 | Human | Cervix | CC | 1.04e-08 | 9.78e-01 | 0.5249 |
1387 | CREBBP | CCI_3 | Human | Cervix | CC | 1.34e-04 | 6.35e-01 | 0.516 |
1387 | CREBBP | HTA11_3410_2000001011 | Human | Colorectum | AD | 4.77e-02 | -2.53e-01 | 0.0155 |
1387 | CREBBP | HTA11_347_2000001011 | Human | Colorectum | AD | 1.63e-03 | 3.68e-01 | -0.1954 |
1387 | CREBBP | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.58e-10 | 7.35e-01 | 0.281 |
1387 | CREBBP | HTA11_99999974143_84620 | Human | Colorectum | MSS | 4.62e-05 | -3.20e-01 | 0.3005 |
1387 | CREBBP | A002-C-010 | Human | Colorectum | FAP | 2.61e-03 | -4.41e-02 | 0.242 |
1387 | CREBBP | A001-C-207 | Human | Colorectum | FAP | 4.79e-02 | -1.54e-01 | 0.1278 |
1387 | CREBBP | A015-C-203 | Human | Colorectum | FAP | 1.13e-31 | -1.57e-01 | -0.1294 |
1387 | CREBBP | A015-C-204 | Human | Colorectum | FAP | 1.14e-04 | -1.59e-01 | -0.0228 |
1387 | CREBBP | A014-C-040 | Human | Colorectum | FAP | 2.45e-03 | -2.10e-01 | -0.1184 |
1387 | CREBBP | A002-C-201 | Human | Colorectum | FAP | 2.72e-11 | -2.76e-01 | 0.0324 |
1387 | CREBBP | A002-C-203 | Human | Colorectum | FAP | 5.95e-07 | -1.19e-02 | 0.2786 |
1387 | CREBBP | A001-C-119 | Human | Colorectum | FAP | 1.31e-05 | 8.61e-02 | -0.1557 |
1387 | CREBBP | A001-C-108 | Human | Colorectum | FAP | 3.05e-16 | -5.21e-02 | -0.0272 |
1387 | CREBBP | A002-C-205 | Human | Colorectum | FAP | 4.95e-22 | -1.06e-01 | -0.1236 |
1387 | CREBBP | A001-C-104 | Human | Colorectum | FAP | 3.58e-04 | 4.17e-03 | 0.0184 |
1387 | CREBBP | A015-C-005 | Human | Colorectum | FAP | 4.36e-03 | -1.38e-01 | -0.0336 |
Page: 1 2 3 4 5 6 7 8 9 10 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00321035 | Cervix | CC | positive regulation of response to external stimulus | 95/2311 | 427/18723 | 5.44e-09 | 5.03e-07 | 95 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00485118 | Cervix | CC | rhythmic process | 65/2311 | 298/18723 | 2.79e-06 | 8.04e-05 | 65 |
GO:00712148 | Cervix | CC | cellular response to abiotic stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:01040048 | Cervix | CC | cellular response to environmental stimulus | 69/2311 | 331/18723 | 7.36e-06 | 1.73e-04 | 69 |
GO:00313494 | Cervix | CC | positive regulation of defense response | 60/2311 | 278/18723 | 9.38e-06 | 2.11e-04 | 60 |
GO:003164710 | Cervix | CC | regulation of protein stability | 63/2311 | 298/18723 | 1.14e-05 | 2.45e-04 | 63 |
GO:003460510 | Cervix | CC | cellular response to heat | 22/2311 | 69/18723 | 1.65e-05 | 3.20e-04 | 22 |
GO:00028315 | Cervix | CC | regulation of response to biotic stimulus | 67/2311 | 327/18723 | 1.79e-05 | 3.36e-04 | 67 |
GO:00093149 | Cervix | CC | response to radiation | 86/2311 | 456/18723 | 3.50e-05 | 5.63e-04 | 86 |
GO:00022533 | Cervix | CC | activation of immune response | 72/2311 | 375/18723 | 8.26e-05 | 1.11e-03 | 72 |
GO:000166610 | Cervix | CC | response to hypoxia | 61/2311 | 307/18723 | 1.04e-04 | 1.34e-03 | 61 |
GO:007048210 | Cervix | CC | response to oxygen levels | 67/2311 | 347/18723 | 1.21e-04 | 1.51e-03 | 67 |
GO:00714786 | Cervix | CC | cellular response to radiation | 41/2311 | 186/18723 | 1.41e-04 | 1.71e-03 | 41 |
GO:00165705 | Cervix | CC | histone modification | 84/2311 | 463/18723 | 1.70e-04 | 2.01e-03 | 84 |
GO:003629310 | Cervix | CC | response to decreased oxygen levels | 62/2311 | 322/18723 | 2.29e-04 | 2.57e-03 | 62 |
GO:00071786 | Cervix | CC | transmembrane receptor protein serine/threonine kinase signaling pathway | 67/2311 | 355/18723 | 2.39e-04 | 2.67e-03 | 67 |
GO:00094089 | Cervix | CC | response to heat | 27/2311 | 110/18723 | 3.12e-04 | 3.32e-03 | 27 |
GO:00022183 | Cervix | CC | activation of innate immune response | 16/2311 | 52/18723 | 3.61e-04 | 3.75e-03 | 16 |
GO:00094112 | Cervix | CC | response to UV | 33/2311 | 149/18723 | 5.51e-04 | 5.29e-03 | 33 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0501618 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa0516720 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa0516620 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa051657 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0516414 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0491918 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
hsa052157 | Cervix | CC | Prostate cancer | 27/1267 | 97/8465 | 7.54e-04 | 3.39e-03 | 2.01e-03 | 27 |
hsa05152 | Cervix | CC | Tuberculosis | 42/1267 | 180/8465 | 1.78e-03 | 7.21e-03 | 4.26e-03 | 42 |
hsa052119 | Cervix | CC | Renal cell carcinoma | 20/1267 | 69/8465 | 2.07e-03 | 8.17e-03 | 4.83e-03 | 20 |
hsa041106 | Cervix | CC | Cell cycle | 36/1267 | 157/8465 | 4.94e-03 | 1.67e-02 | 9.86e-03 | 36 |
hsa0501619 | Cervix | CC | Huntington disease | 94/1267 | 306/8465 | 8.49e-13 | 3.06e-11 | 1.81e-11 | 94 |
hsa05167110 | Cervix | CC | Kaposi sarcoma-associated herpesvirus infection | 60/1267 | 194/8465 | 9.74e-09 | 1.58e-07 | 9.33e-08 | 60 |
hsa04520110 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa05166110 | Cervix | CC | Human T-cell leukemia virus 1 infection | 61/1267 | 222/8465 | 8.13e-07 | 7.98e-06 | 4.72e-06 | 61 |
hsa0516512 | Cervix | CC | Human papillomavirus infection | 74/1267 | 331/8465 | 1.70e-04 | 1.02e-03 | 6.03e-04 | 74 |
hsa0431012 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0516415 | Cervix | CC | Influenza A | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa0491919 | Cervix | CC | Thyroid hormone signaling pathway | 33/1267 | 121/8465 | 3.11e-04 | 1.65e-03 | 9.78e-04 | 33 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CREBBP | SNV | Missense_Mutation | novel | c.6007N>T | p.Pro2003Ser | p.P2003S | Q92793 | protein_coding | deleterious(0.03) | benign(0) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
CREBBP | SNV | Missense_Mutation | novel | c.1387N>T | p.Gly463Trp | p.G463W | Q92793 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-XK-AAIW-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 9 | Unknown | Unknown | PD |
CREBBP | deletion | Frame_Shift_Del | novel | c.6597_6609delGCAGCAGCAGCAA | p.Gln2199HisfsTer99 | p.Q2199Hfs*99 | Q92793 | protein_coding | TCGA-EJ-7115-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD | ||
CREBBP | SNV | Missense_Mutation | rs758740001 | c.535N>A | p.Ala179Thr | p.A179T | Q92793 | protein_coding | tolerated_low_confidence(0.24) | benign(0.066) | TCGA-BR-4201-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | cisplatin | SD |
CREBBP | SNV | Missense_Mutation | c.2843N>G | p.Gln948Arg | p.Q948R | Q92793 | protein_coding | tolerated(0.25) | probably_damaging(0.953) | TCGA-BR-4361-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CREBBP | SNV | Missense_Mutation | c.6431N>T | p.Ala2144Val | p.A2144V | Q92793 | protein_coding | tolerated_low_confidence(0.09) | benign(0.018) | TCGA-BR-6452-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CREBBP | SNV | Missense_Mutation | rs781364836 | c.5063N>T | p.Thr1688Met | p.T1688M | Q92793 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-BR-7851-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | c.4556N>G | p.Tyr1519Cys | p.Y1519C | Q92793 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BR-7851-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
CREBBP | SNV | Missense_Mutation | rs867855180 | c.4039N>T | p.Arg1347Trp | p.R1347W | Q92793 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-BR-8081-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CREBBP | SNV | Missense_Mutation | rs150767375 | c.2438N>T | p.Pro813Leu | p.P813L | Q92793 | protein_coding | deleterious(0) | possibly_damaging(0.792) | TCGA-BR-8081-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | (-)-ROLIPRAM | (-)-ROLIPRAM | ||
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | ETAZOLATE | ETAZOLATE | ||
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | TRIAZOLAM | TRIAZOLAM | 22137933 | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | DNDI1417457 | CHEMBL1530911 | ||
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | ESTAZOLAM | ESTAZOLAM | 22137933 | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | DIETHYL-2-TETRADECYLMALONATE | CHEMBL1797712 | 21292492 | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | PAPAVERINE | PAPAVERINE | ||
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | C 82 | |||
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | DIETHYL-2-TETRADECYLIDENEMALONATE | CHEMBL257748 | 21292492 | |
1387 | CREBBP | CLINICALLY ACTIONABLE, TRANSCRIPTION FACTOR COMPLEX, ENZYME, TRANSCRIPTION FACTOR, DRUG RESISTANCE, DRUGGABLE GENOME | PRI-724 | PRI-724 |
Page: 1 2 3 |